Genedrive PLC (GB:GDR)
LSE:GDR
Want to see GB:GDR full AI Analyst Report?
Top Page
Genedrive
(LSE:GDR)
Select Model
Select Model
Rating:49Neutral
Price Target:
1.00 p
▲(13.64% Upside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weak financial performance: large ongoing losses, sustained cash burn, and a shrinking equity base despite low debt. Technicals are a partial offset with price trading above major moving averages and generally neutral momentum indicators, while valuation remains constrained by negative earnings and no dividend yield data.
Positive Factors
Recurring consumables revenue
Genedrive's business model sells instruments plus single-use test cartridges, creating a recurring consumables revenue stream tied to installed base. This durable revenue mix supports predictability and higher lifetime customer value as installed instruments drive future kit demand.
Negative Factors
Persistent negative cash flow
Material negative operating and free cash flow indicate the business is not self-funding and will likely need external capital to sustain operations or expand. Ongoing cash burn reduces runway, increases financing dependence, and elevates dilution risk over the next 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
Genedrive's business model sells instruments plus single-use test cartridges, creating a recurring consumables revenue stream tied to installed base. This durable revenue mix supports predictability and higher lifetime customer value as installed instruments drive future kit demand.
Read all positive factors
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£20.07M
Dividend YieldN/A
Average Volume (3M)49.58M
Price to Earnings (P/E)―
Beta (1Y)-0.58
Revenue Growth65.60%
EPS Growth74.84%
CountryUK
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genedrive Business Overview & Revenue Model
Company Description
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented...
How the Company Makes Money
Genedrive makes money primarily through (1) sales of its Genedrive diagnostic instruments (capital equipment placed with laboratories, hospitals, or clinics) and (2) recurring revenue from consumables—single-use/disposable test cartridges or assay...
Genedrive Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07M | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 898.00K | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.58M | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.34M | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | ||||||
| Total Assets | 1.75M | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 387.00K | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 500.00K | 0.00 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 2.17M | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | -415.00K | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | ||||||
| Free Cash Flow | -3.90M | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -3.89M | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -10.00K | -23.00K | 1.00K | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 2.19M | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Positive
0.88
Price Trends
1.04
Positive
1.04
Positive
0.86
Positive
Market Momentum
0.08
Negative
61.39
Neutral
50.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GDR, the sentiment is Positive. The current price of 0.88 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.04, and above the 200-day MA of 0.86, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 61.39 is Neutral, neither overbought nor oversold. The STOCH value of 50.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:GDR.
Genedrive Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £114.51M | 55.78 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £32.23M | -14.62 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.07M | -2.10 | -153.92% | ― | 65.60% | 74.84% | |
49 Neutral | £1.36B | -8.62 | -29.43% | ― | 22.22% | 7.19% | |
40 Underperform | £18.14M | -5.62 | -213.66% | ― | 13.42% | 65.63% | |
39 Underperform | £7.87M | -0.33 | 425.97% | ― | ― | ― |
* Healthcare Sector Average
GB:GDR
Genedrive
1.33
-0.16
-10.59%
GB:EKF
EKF Diagnostics Holdings
26.40
-0.60
-2.22%
GB:RENX
Renalytix
1.85
-5.40
-74.48%
GB:ABDX
Abingdon Health PLC
12.00
5.25
77.78%
GB:APTA
Aptamer Group Plc
0.53
0.19
54.41%
GB:ONT
Oxford Nanopore Technologies PLC
130.30
10.30
8.58%
Genedrive Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Genedrive Secures £0.76m R&D Tax Credit to Support Expansion of Point-of-Care Genetics
Positive
Jun 5, 2026
Genedrive plc, a Manchester-headquartered pharmacogenetic diagnostics company focused on point-of-care tests for personalised prescribing, has built a portfolio that includes two CE-IVD approved and NICE-recommended assays deployed in NHS settings...
Business Operations and StrategyRegulatory Filings and Compliance
Genedrive Reports No Change in Share Option Scheme Balances in Latest Block Listing Return
Positive
Jun 1, 2026
Genedrive plc has confirmed its latest six‑monthly block listing return, reporting no changes in the number of securities available under its 2007 Share Option Scheme, 2017 Share Option Scheme and Unapproved Share Option Scheme for the perio...
Regulatory Filings and Compliance
Genedrive Reports No Share Issuance in Latest Block Listing Return
Positive
Jun 1, 2026
Genedrive plc has reported its latest six-monthly block listing return, confirming that no new shares were issued or allotted under its 2007 Share Option Scheme, 2017 Share Option Scheme, or Unapproved Share Option Scheme for the period from 1 Dec...
Business Operations and StrategyExecutive/Board Changes
Genedrive reshapes board as major shareholder joins and long-serving chairman prepares exit
Positive
May 26, 2026
Genedrive has strengthened its governance by appointing major shareholder David Nugent, who holds more than a quarter of the company’s shares and recently acted as a cornerstone investor in its February equity financing, as a non-executive d...
Business Operations and StrategyProduct-Related Announcements
Genedrive Test Adopted as Routine Neonatal Service at Sussex NHS Trust
Positive
May 5, 2026
Genedrive plc said University Hospitals Sussex NHS Foundation Trust has moved its Genedrive MT-RNR1 ID kit for preventing antibiotic-induced hearing loss in neonatal intensive care units to a Business as Usual clinical service from 1 May 2026. The...
Business Operations and StrategyProduct-Related Announcements
Genedrive Positioned for NHS Tender as Rapid MT-RNR1 Test Expands Across UK NICUs
Positive
Apr 21, 2026
Genedrive, a Manchester-headquartered pharmacogenetic testing specialist focused on rapid point-of-care diagnostics for acute settings, already supplies two NICE-recommended genetic tests in NHS clinical use, targeting stroke treatment optimisatio...
Business Operations and Strategy
Genedrive Enhances Investor Hub to Deepen Shareholder Engagement
Positive
Apr 20, 2026
Genedrive plc has upgraded its interactive investor hub, aiming to make it a centralised platform for shareholder communication as the company advances its commercial and clinical activities in pharmacogenetic testing. The hub allows investors to ...
Business Operations and StrategyProduct-Related Announcements
Genedrive Secures Charity-Backed Rollout of Stroke Test at Bristol’s Southmead Hospital
Positive
Apr 16, 2026
Genedrive plc’s CYP2C19 ID Kit is set to be implemented at North Bristol NHS Trust’s Southmead Hospital Hyperacute and Acute Stroke Units, backed by £80,000 in funding from the Medlock Charitable Trust, whose chair David Medlock i...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Genedrive bolsters finances as NHS and global pilots drive uptake of rapid genetic tests
Positive
Mar 30, 2026
Genedrive reported interim results to 31 December 2025, highlighting increased revenue but a stable operating loss as it invests in commercial expansion for its CYP2C19 and MT-RNR1 pharmacogenetic tests in the UK and abroad. The company has secure...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genedrive shareholders back fundraising as company expands pharmacogenetic footprint
Positive
Mar 9, 2026
Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops and commercialises rapid, low‑cost point‑of‑care genetic tests that enable clinicians to tailor drug choice and dosage, with a focus on emergenc...
Business Operations and StrategyPrivate Placements and Financing
Genedrive Raises £5.26 Million to Bolster Point-of-Care Pharmacogenetics Push
Positive
Mar 9, 2026
Genedrive plc, a UK-listed point-of-care pharmacogenetic testing specialist, focuses on rapid, low-cost genetic diagnostics that enable clinicians to tailor drug choice and dosage, with particular emphasis on emergency healthcare settings. The com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.